Stockreport

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

INmune Bio Inc. - Common stock  (INMB) 
PDF BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues t [Read more]